Contact Us
To learn more about the program, contact Jill Bischoff at jbischoff@cop.ufl.edu or 352-294-5157.

About the CTSI
The UF CTSI works on many fronts to improve research and health. It provides resources for research teams, career development programs, pilot project funding and an extensive network of local, state and national partners.

CTSI Web Portal
Visit the CTSI’s website for information about additional programs and research services: www.ctsi.ufl.edu.

CTSI Listserv
Subscribe to the CTSI listserv by emailing Claire Baralt at cbaralt@ufl.edu.

The UF CTSI is supported by NIH Clinical and Translational Science Awards UL1 TR000064, KL2 TR000065 and TL1 TR000066, and by significant matching commitments from UF’s Office of Research and College of Medicine.

UF Health
Personalized Medicine Program

Led by the UF Clinical and Translational Science Institute, the UF Health Personalized Medicine Program was established in 2011 to prepare UF Health and the state of Florida to be leaders in genomic medicine. The program is utilizing and advancing many elements of the UF CTSI to develop a transformational capability for improving care while creating new opportunities for translational research. Over the course of one year, the program created the clinical, laboratory and informatics infrastructure required to generate electronic medical record alerts that allow UF Health clinicians to take a patient’s genetic information into account when prescribing certain medications. In June 2012, the program launched clinically with an initial focus on clopidogrel for interventional cardiology patients. See reverse for a summary of program funding and milestones.

Guiding Principles
Three guiding principles shape the program’s approach:

- Ensure a regulatory body is in place to evaluate the scientific literature and determine when sufficient evidence exists for the health system to consider genetic findings clinically actionable
- Provide actionable alerts for healthcare providers through the electronic medical record system and backup support by clinical pharmacists
- Develop the capacity to perform a one-time, evidence-based genetic test that screens for hundreds of genetic variations that can be used across a patient’s lifespan

With support from a $3.7 million implementation grant awarded in June 2013 by the National Human Genome Research Institute, the program is expanding in three ways over the next four years:

- **Expansion at UF Health**
  Utilizing the program’s infrastructure—which facilitates the complex clinical, laboratory and information flows required for genomic medicine—UF Health will introduce routine genetic testing for additional medications for which there is strong evidence linking specific genetic variations to how the body responds to a drug. In 2013, the program will expand beyond clopidogrel to focus on azathioprine for adult and pediatric gastroenterology patients with Crohn’s disease and other conditions; and mercaptopurine for pediatric cancer patients with acute lymphocytic leukemia.

- **Expansion to Private and Community Practices in Florida**
  Beginning in 2013, the UF Health program will help Orlando Health prepare two of its cardiology practices to implement genetic testing for clopidogrel in 2014. Following the Orlando Health implementation, the program will work with the Florida State University College of Medicine to introduce similar genetic testing within its statewide network of community-based physician practices. UF Health Pathology Laboratories, which developed the infrastructure to process the blood samples from patients, will offer its services and expertise for the expansion at UF Health and to external partners.

- **Development of Educational Programs**
  To complement its clinical implementations, the program will develop and offer a variety of innovative educational programs to prepare health-care professionals, health sciences students and patients for a future in which genomic medicine is commonplace.
### Program Funding & Milestones

- **June 2011:** UF Health receives two grants from the National Institutes of Health to support the creation and launch of a new Personalized Medicine Program led by the UF CTSI:
  - One-year grant of $499,920 through the Clinical and Translational Science Awards program, led by the NIH National Center for Advancing Translational Sciences, to create the program and replicate it at Stanford University;
  - Four-year grant of $351,600 from the National Institute of General Medical Sciences, the lead institute for the NIH Pharmacogenomics Research Network, to collaborate with five other institutions to collectively gather data on the experience of launching personalized medicine programs: Vanderbilt University, Mayo Clinic, Ohio State University, University of Maryland and St. Jude Children’s Research Hospital.

- **June 2012:** Program launches at UF Health Shands Hospital, which incorporates a simple blood test for interventional cardiology patients that provides genetic information indicating how an individual will likely respond to clopidogrel, an anticlotting drug commonly prescribed following treatment in the catheterization lab for blocked heart vessels. During the program’s first year, more than 1,000 patients at the UF Health cardiac catheterization lab received this routine genetic test, approximately 28% of whom have genetic variations contra-indicated for clopidogrel.

- **October 2012:** Program launches ongoing research study to test feasibility of preemptive genotyping.

- **June 2013:** UF Health receives a four-year grant of $3.7 million to expand the program through the Genomic Medicine Pilot Demonstration Projects Program, which is led by the NIH’s National Human Genome Research Institute and supports a network of projects at Duke University and Mount Sinai plus a coordinating center at the University of Pennsylvania.